Biotechnology

Vera Therapeutics

NVIDIA

Conference Minutes

OpenAI

NVDA

MSFT

DXYZ

CRWV

VERA

ORCL

OPEN

002245

NVDL

07788

07388

NVDY

NVDD

NVDX

NVDQ

MSFL

MSFO

MSFD

<p>The following are the minutes of NVIDIA's FY2026 Q3 earnings call, compiled by Dolphin Research. For an interpretation of the earnings report, please refer to the article 'More Important Than Non-Farm Payrolls! Can NVIDIA Save the US Stock Market Again?' Compared to the earnings report, the information conveyed in this earnings call is more critical: ① Data Center Revenue: GB300 sales surpassed GB200, contributing about two-thirds of Blackwell's total revenue. Hopper revenue was approximately $2 billion, with H20 accounting for about $50 million; Regarding guidance: the company provided revenue guidance for the next quarter...</p>

ISHRS S Arabia

Microsoft

Destiny Tech100

Coreweave

Oracle

Opendoor Tech

Jiangsu Azure Corporation

GraniteShares 2x Long NVDA Daily ETF

XL2CSOPNVDA

XI2CSOPNVDA

YieldMax NVDA Option Income Strategy ETF

Direxion Daily NVDA Bear 1X ETF

T-Rex 2X Long NVIDIA Daily Target ETF

T-Rex 2X Inverse NVIDIA Daily Target ETF

GraniteShares 2x Long MSFT Daily ETF

YieldMax MSFT Option Income Strategy ETF

Direxion Daily MSFT Bear 1x Shares

NVIDIA (Minutes): Target gross margin for next year is 75%, collaboration with OpenAI is not blind

Vera Therapeutics Submits BLA for Atacicept to FDA

Vera Therapeutics released FY2025 9 Months Earnings on November 5, 2025 (EST), with actual revenue of USD 0 and EPS of USD -3.2692

Vera Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2599 (forecast USD -1.1766)

Rami Katkhuda Maintains Buy Rating on Vera Therapeutics

Vera Therapeutics to Present Atacicept Phase 3 Clinical Data for IgA Nephropathy at 2025 ASN Kidney Week

Vera Therapeutics ORIGIN 3 abstract selected for oral presentation at 2025 ASN Kidney Week

Vera Therapeutics to present atacicept Phase III trial data at ASN Kidney Week 2025

Stavropoulos Maintains Strong Buy Rating on Vera Therapeutics Stock

Clark-Gartner Rates Vera Therapeutics Strong Buy with a Target Price

Vera Therapeutics released FY2025 Q2 earnings on August 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2 (forecast USD -0.702)

Vera Therapeutics released FY2025 Semi-Annual earnings on August 5 (EST), actual revenue USD 0, actual EPS USD -2.0119

Vera Therapeutics receives consistent analyst recommendation

Vera Therapeutics Grants Stock Incentives to New Employees

Vera Therapeutics reports $50.9m debt but holds $589.8m in cash

Vera Therapeutics Director Acquires Common Stock

Vera Therapeutics Grants Stock Options and RSUs to New Employees

FactSet: Vera Therapeutics Rated Buy

Vera Therapeutics Stock Dips After Competitor's Positive Trial Results

Scotiabank Raises Vera Therapeutics Target Price

Vera Therapeutics Secures $500 Million Term Loan Facility from Oxford Finance

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

Foxx Development

Palatin Tech

Mobile-Health Network Solutions

Nuvve

Datavault AI

CCSC Tech

Iveda Solutions

Harrison Global

Alps